Antiviral Drugs Market Size, Share and Forecast Trends - Growth Analysis and Outlook Report 2026-2030

The global antiviral drugs market encompasses medications used to treat viral infections by inhibiting viral replication within the human body. This therapeutic class spans a wide range of drug categories, from nucleoside analogues to protease inhibitors, targeting both acute and chronic viral diseases.

• •Estimated at $71.3 billion in 2025, with projected growth toward approximately $95-103 billion by the early-to-mid 2030s at a CAGR of roughly 4%
• •Covers major disease areas including HIV/AIDS, hepatitis, influenza, herpesviruses, and respiratory viruses such as COVID-19
• •North America dominates the global market, accounting for roughly 39% of total revenue in 2025

Several interconnected factors are propelling the market forward. Rising prevalence of chronic viral infections such as HIV and hepatitis continues to sustain robust demand for long-term antiviral therapy. Simultaneously, technological advancements in drug discovery, including improved formulations and novel delivery mechanisms, are expanding the accessible patient population.

• •Continued high burden of HIV and hepatitis infections, driving steady demand for branded and generic antiretroviral therapies
• •Growing adoption of antiviral treatments in hospital and outpatient settings worldwide
• •Expanding antiviral drug pipelines, including new classes targeting influenza, RSV, and other respiratory viruses

The market is segmented by drug class, application, route of administration, and geography. Nucleoside/nucleotide analogues, protease inhibitors, and polymerase inhibitors constitute the most prominent drug classes, while oral formulations dominate the administration segment due to patient convenience.

• •North America leads globally, followed by Europe and the Asia-Pacific region, where rising healthcare access is accelerating uptake
• •HIV therapeutics remain the single largest application segment, with hepatitis and influenza therapeutics representing significant sub-markets
• •Branded drugs continue to hold major market share, though the biosimilar and generic segment is expanding as patent expirations increase

What are the recent trends and outlook?

Looking ahead, the market is expected to remain on a positive growth trajectory through the 2030s. Advances in targeted therapies, combination regimens, and long-acting formulations are anticipated to reshape treatment paradigms and improve patient outcomes.

• •Increased focus on preventive antiviral therapies and vaccine-antiviral combination approaches
• •Rising interest in broad-spectrum antivirals capable of addressing multiple viral families
• •Expanding access in low- and middle-income countries through tiered pricing, patent pools, and local manufacturing initiatives